Fatigue - Pipeline Review, H2 2016

Date: July 13, 2016
Pages: 55
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: FDB22930864EN
Leaflet:

Download PDF Leaflet

Fatigue - Pipeline Review, H2 2016

Summary

Global Markets Direct’s, ‘Fatigue - Pipeline Review, H2 2016’, provides an overview of the Fatigue pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Fatigue, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Fatigue and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape of Fatigue
  • The report reviews pipeline therapeutics for Fatigue by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Fatigue therapeutics and enlists all their major and minor projects
  • The report assesses Fatigue therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Fatigue
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Fatigue
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Fatigue pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Fatigue Overview
Therapeutics Development
Pipeline Products for Fatigue - Overview
Fatigue - Therapeutics under Development by Companies
Fatigue - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Fatigue - Products under Development by Companies
Fatigue - Companies Involved in Therapeutics Development
BioLite, Inc.
Biovista Inc.
Grifols, S.A.
Hemispherx Biopharma, Inc.
MultiCell Technologies, Inc.
Fatigue - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(lofepramine hydrochloride + phenylalanine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alpha-1 proteinase inhibitor (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLI-1402 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant A1PI - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Chronic Fatigue Syndrome and Myalgic Encephalomyelitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fatigue - Dormant Projects
Fatigue - Product Development Milestones
Featured News & Press Releases
Jun 07, 2016: Hemispherx Biopharma: Dr. William M. Mitchell Publishes Article Titled, “Efficacy of Rintatolimod in the Treatment of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)” in Expert Review of Clinical Pharmacology
Mar 10, 2016: Hemispherx Biopharma Reviews Ampligen Data with National Institute of Neurological Disorders and Stroke
Sep 21, 2015: Hemispherx Biopharma Research Team Identifies Characteristics of Chronic Fatigue Syndrome Patients Potentially Predictive of Improved Response to Ampligen
Sep 17, 2015: Hemispherx Biopharma Announces Patient Assistance Program for Chronic Fatigue Syndrome Open Label Study
Sep 15, 2015: Hemispherx Biopharma Reports Low NK Cell Activity in Chronic Fatigue Syndrome and Relationship to Disease Symptoms
Aug 10, 2015: Hemispherx Enters into an Agreement with myTomorrows for an Early Access Program for Rintatolimod in Europe
Jun 25, 2015: Hemispherx Receives the European Patent Office Examining Division’s Notice of Intention to Grant the New Composition of Matter Patent Covering Ampligen Formulations
May 27, 2014: Hemispherx Receives New U.S. Composition of Matter Patent Covering Ampligen Formulations
May 21, 2014: Hemispherx and GP Pharm Agree to Establish a Manufacturing Operation in Argentina to Serve Latin America Markets and Ancillary Markets
Mar 24, 2014: Hemispherx Biopharma Presented Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
Mar 19, 2014: Hemispherx Biopharma, Inc. to Present Clinical Interpretations on CFS Treatment at the 11th Biennial International Research and Clinical Conference
Mar 10, 2014: Hemispherx Biopharma Announces Plans to File for Regulatory Approval of Ampligen to Treat Chronic Fatigue Syndrome in Three Additional Latin America Countries
Feb 04, 2013: Hemispherx Biopharma Fails To Win FDA Approval For Its Chronic Fatigue Drug Ampligen
Dec 21, 2012: Hemispherx Biopharma Announces Outcome Of FDA Meeting On Ampligen
Oct 22, 2012: Hemispherx Biopharma Announces FDA Confirms Advisory Committee Meeting On December 20, 2012
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Fatigue, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Fatigue - Pipeline by BioLite, Inc., H2 2016
Fatigue - Pipeline by Biovista Inc., H2 2016
Fatigue - Pipeline by Grifols, S.A., H2 2016
Fatigue - Pipeline by Hemispherx Biopharma, Inc., H2 2016
Fatigue - Pipeline by MultiCell Technologies, Inc., H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Fatigue - Dormant Projects, H2 2016

LIST OF FIGURES

Number of Products under Development for Fatigue, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Mechanism of Actions, H2 2016
Number of Products by Stage and Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Parkinson's Disease - Pipeline Review, H2 2015 US$ 2,125.00 Dec, 2015 · 838 pages

Ask Your Question

Fatigue - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: